Symptomatic remission in previously untreated patients with schizophrenia: 2-Year results from the SOHO study

Psychopharmacology

Volumn 191, Issue 4, 2007, Pages 1015-1022

  Novick, Diego ^a   Haro, Josep Maria ^b   Suarez, David ^b   Lambert, Martin ^c   Lépine, Jean Pierre ^d   Naber, Dieter ^c  

^a ELI LILLY AND COMPANY   (United States)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d HÔPITAL FERNAND WIDAL   (France)

Author keywords

Antipsychotics; Clinical outcome; Schizophrenia; Symptom remission

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947149079     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0730-2     Document Type: Article

References (45)

1. Addington J, Brooks BL, Addington D (2003) Cognitive functioning in first episode psychosis: initial presentation. Schizophr Res 62:59-64
2. Altamura AC, Bassetti, R, Sassella F, Salvadori D, Mundo E (2001) Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 52:29-36
3. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449
4. Ascher-Svanum H, Stensland M, Kinon J, Tollefson GD (2005) Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 19(6 Suppl):110-117
5. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA (2000) Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157:549-559
6. Bottlender R, Sato T, Jager M, Wegener U, Wittmann J, Strauss A, Moller HJ (2003) The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr Res 62:37-44
7. Bustillo JR, Buchana RW, Irish D, Breier A (1996) Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 153:817-819
8. Ciompi L (1980) Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull 6:606-618
9. Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158:765-774
10. Curran MP, Perry CM (2002) Spotlight on amisulpride in schizophrenia. CNS Drugs 16:207-211
11. Cutler AJ, Goldstein JM, Tumas JA (2002) Dosing and switching strategies for quetiapine fumarate. Clin Ther 24:209-222
12. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA (2002) Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 22:244-251
13. Guy G (1976) Clinical global impression. In: ECDEU assessment manual for psychopharmacology, revised. National Institute of Mental Health, Rockville, MD
14. Hafner H, An der Heiden W (1997) Epidemiology of schizophrenia. Can J Psychiatry 42:139-151
15. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A (1987) The Vermont longitudinal study of persons with severe mental illness, II: long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry 144:727-735
16. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fragas A, Rodriguez MJ, Rele R, Orta J, Kharbeng A, Araya S, Gervin M, Alonso J, Mavreas V, Lavrentzou E, Liontos N, Gregor K, Jones PB, on behalf of the SOHO study group (2003a) The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 107(Suppl 416):16-23
17. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB, on behalf of the SOHO study group (2003b) The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 107(Suppl 416):1-9
18. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, Wright P, Knapp M, on behalf of the SOHO study group (2003c) The European Schizophrenia Outpatient Health Outcomes (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand 107:222-232
19. Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, Jones PB, Ratcliffe M, Breier A, on behalf of the SOHO Advisory Board (2005) Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) Study. Acta Psychiatr Scand 111:220-231
20. Haro JM, Novick D, Belger M, Jones PB, SOHO Advisory Board (2006a) Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Psychiatr 21:41-47
21. Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F (2006b) Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy 5:11-25
22. Haro JM, Ochoa S, Gervin M, Mavreas V, Jones P (2007) Assessment of remission in schizophrenia with the CGI and CGI-SCH scales [Letter]. Acta Psychiatr Scand 115:163-164
23. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, Holmberg SK, Janca A, Lee PWH, Leon CA, Malhotra S, Marsella AJ, Nakane Y, Sartorius N, Shen Y, Skoda C, Thara R, Tsirkin SJ, Varma VK, Walsh D, Wiersma D (2001) Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 178:506-517
24. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC (1998) Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 155:1196-1201
25. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE (1999) Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 156:1336-1341
26. Huber G, Gross G, Schuttler R (1975) A long term follow-up study of schizophrenia psychiatric course of illness and prognosis. Acta Psychiatr Scand 52:49-57
27. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087
28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
29. Marwaha S, Johnson S (2004) Schizophrenia and employment - a review. Soc Psychiatry Psychiatr Epidemiol 39:337-349
30. Meltzer HY, Perry E, Jayathilake K (2003) Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 59:19-27
31. Milev P, Ho BC, Arndt S, Andreasen NC (2005) Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 162:495-506
32. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R (2005) Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 56:273-282
33. Naudts K, Hodgins S (2006) Neurobiological correlates of violent behavior among persons with schizophrenia. Schizophr Bull 32:562-572
34. Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, Edgell ET, Ratcliffe M, and the SOHO advisory board (2005) Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) Study. Prog Neuropsychoparmacol Biol Psychiatry 29:972-982
35. Oosthuizen P, Emsley RA, Roberts MC, Turner J, Keyter L, Keyter N, Torreman M (2002) Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia. Schizophr Res 58:247-252
36. Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, Weizman A (2002) Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry 159:1058-1060
37. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 161:473-479
38. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD (1999) Olanzapine vs haloperidol treatment in first-episode psychosis. Am J Psychiatry 156:79-87
39. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eedekens M, Swyzen W, de Smedt G, Early Psychosis Global Working Group (2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162:947-953
40. Shepherd M, Watt D, Fallon I, Smeeton N (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med, monograph supplement 15:1-46
41. Takahashi H, Yoshida K, Ishigooka J, Higuchi H (2006) Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog Neuropsychopharmacol Biol Psychiatry 30:1067-1072
42. Tiihonen J, Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224
43. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaboration study. Am J Psychiatry 154:457-465
44. Williams A (1990) Euro-QoL - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
45. Wiselgren IM, Lindstrom E, Lindstrom LH (1996) Symptoms at index admission as predictor for 1-5 year outcome in schizophrenia. Acta Psychiatr Scand 94:311-319